UBS Group
NVCT icon

UBS Group’s Nuvectis Pharma NVCT Stock Holding History

UBS Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
69,200
+30,637
+79% +$343K ﹤0.01% 5520
2026
Q1 		$298K Buy
38,563
+30,188
+360% +$259K ﹤0.01% 6410
2025
Q4 		$63.2K Sell
8,375
-17,094
-67% -$111K ﹤0.01% 7114
2025
Q3 		$153K Buy
25,469
+15,211
+148% +$105K ﹤0.01% 6828
2025
Q2 		$76.6K Sell
10,258
-101,262
-91% -$918K ﹤0.01% 7446
2025
Q1 		$1.09M Buy
111,520
+108,851
+4,078% +$784K ﹤0.01% 5216
2024
Q4 		$14.4K Buy
2,669
+2,658
+24,164% +$16.6K ﹤0.01% 8095
2024
Q3 		$69 Sell
11
-2
-15% -$13 ﹤0.01% 9201
2024
Q2 		$82 Sell
13
-7,607
-100% -$51.7K ﹤0.01% 9187
2024
Q1 		$62.5K Sell
7,620
-440
-5% -$3.74K ﹤0.01% 6418
2023
Q4 		$67.2K Buy
8,060
+4,284
+113% +$38.2K ﹤0.01% 6391
2023
Q3 		$48.7K Sell
3,776
-203
-5% -$2.94K ﹤0.01% 6302
2023
Q2 		$63.5K Buy
+3,979
New +$63.5K ﹤0.01% 6331
2022
Q4 		– Sell
-220
Closed -$2K – 11011
2022
Q3 		$2K Buy
220
+158
+255% +$1.47K ﹤0.01% 9750
2022
Q2 		$1K Sell
62
-79
-56% -$977 ﹤0.01% 9922
2022
Q1 		$1K Buy
+141
New +$981 ﹤0.01% 9893

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

UBS Group's NVCT Position: Q2 2026 in Review

UBS Group increased its Nuvectis Pharma (NVCT) stake by 79% in Q2 2026, buying an estimated $343K and bringing the position to 69,200 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #5520.

UBS Group first reported a position in NVCT in Q1 2022 and has held it in 16 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • UBS Group held 69,200 shares of Nuvectis Pharma worth $1.27M as of Q2 2026.
  • UBS Group bought 30,637 Nuvectis Pharma shares in Q2 2026, an estimated $343K.
  • Nuvectis Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5520 holding.
  • UBS Group first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 16 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.